<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">placebo plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 3em;">pembrolizumab plus SoC <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (7) progression or deaths (PFS) (7) objective responses (ORR) (7) DOR (6) TRAE (any grade) (3) AE (any grade) (2) AE leading to treatment discontinuation (any grade) (2) AE (grade 3-4) (2) AE leading to death (grade 5) (2) TRAE leading to discontinuation (grade 3-4) (1) TRAE (grade 3-4) (1) TRAE leading to death (grade 5) (1) TRAE leading to discontinuation (any grade) (1) STRAE (any grade) (1) STRAE (grade 3-4) (1) Peripheral neuropathy TRAE (grade 3-4) (4) Fatigue TRAE (grade 3-4) (3) Nausea TRAE (grade 3-4) (3) Diarrhoea TRAE (grade 3-4) (3) Decreased appetite TRAE (grade 3-4) (3) Asthenia TRAE (grade 3-4) (3) Anaemia TRAE (grade 3-4) (3) Thrombocytopenia TRAE (grade 3-4) (3) Neutropenia TRAE (grade 3-4) (3) Vomiting TRAE (grade 3-4) (3) Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4) (3) Pruritus TRAE (grade 3-4) (2) Rash TRAE (grade 3-4) (2) Hypothyroidism TRAE (grade 3-4) (2) Leucopenia TRAE (grade 3-4) (2) Alopecia TRAE (grade 3-4) (2) Mucosal inflammation TRAE (grade 3-4) (2) Constipation TRAE (grade 3-4) (2) Weight decreased TRAE (grade 3-4) (2) Dysgeusia TRAE (grade 3-4) (2) Stomatitis TRAE (grade 3-4) (2) Dry skin TRAE (grade 3-4) (2) Blood creatinine increased TRAE (grade 3-4) (2) Dizziness TRAE (grade 3-4) (2) Peripheral sensory neuropathy TRAE (grade 3-4) (2) Renal and urinary disorders TRAE (grade 3-4) (1) Increased ALT TRAE (grade 3-4) (1) Increased lipase level TRAE (grade 3-4) (1) Skin and subcutaneous tissue disorders TRAE (grade 3-4) (1) Gastrointestinal disorders TRAE (grade 3-4) (1) Increase AST TRAE (grade 3-4) (1) Hepatobiliary disorders TRAE (grade 3-4) (1) Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) (1) Endocrine disorders TRAE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 KEYNOTE-062 (P vs C ; CPS>10), 2020
KEYNOTE-062 (P vs C ; CPS>1), 2020 2 CheckMate 649 (PDL1 CPS>5), 2021
CheckMate 649, 2021 2 KEYNOTE-062 (PC vs C ; CPS>1), 2020
KEYNOTE-062 (PC vs C ; CPS>10), 2020 nivolumab plus SoC vs. pembrolizumab alone
0.90 [0.73; 1.11] 0.90 [0.73;1.11]nivolumab plus SoC vs. pembrolizumab alone
0.90 [0.73; 1.11] nivolumab plus SoC vs. pembrolizumab plus SoC
0.89 [0.73; 1.10] 0.89 [0.73;1.10]nivolumab plus SoC vs. pembrolizumab plus SoC
0.89 [0.73; 1.10] nivolumab plus SoC vs. Standard of Care (SoC)
nivolumab plus SoC better
0.76 [0.67; 0.86] 0.76 [0.67;0.86]nivolumab plus SoC vs. Standard of Care (SoC)
nivolumab plus SoC better
0.76 [0.67; 0.86] pembrolizumab alone vs. nivolumab plus SoC
1.12 [0.90; 1.38] 1.12 [0.90;1.38]pembrolizumab alone vs. nivolumab plus SoC
1.12 [0.90; 1.38] pembrolizumab alone vs. pembrolizumab plus SoC
1.00 [0.79; 1.27] 1.00 [0.79;1.27]pembrolizumab alone vs. pembrolizumab plus SoC
1.00 [0.79; 1.27] pembrolizumab alone vs. Standard of Care (SoC)
0.85 [0.71; 1.01] 0.85 [0.71;1.01]pembrolizumab alone vs. Standard of Care (SoC)
0.85 [0.71; 1.01] pembrolizumab plus SoC vs. nivolumab plus SoC
1.12 [0.91; 1.37] 1.12 [0.91;1.37]pembrolizumab plus SoC vs. nivolumab plus SoC
1.12 [0.91; 1.37] pembrolizumab plus SoC vs. pembrolizumab alone
1.00 [0.79; 1.27] 1.00 [0.79;1.27]pembrolizumab plus SoC vs. pembrolizumab alone
1.00 [0.79; 1.27] pembrolizumab plus SoC vs. Standard of Care (SoC)
0.85 [0.72; 1.00] 0.85 [0.72;1.00]pembrolizumab plus SoC vs. Standard of Care (SoC)
0.85 [0.72; 1.00] Standard of Care (SoC) vs. nivolumab plus SoC
nivolumab plus SoC better
1.31 [1.16; 1.49] 1.31 [1.16;1.49]Standard of Care (SoC) vs. nivolumab plus SoC
nivolumab plus SoC better
1.31 [1.16; 1.49] Standard of Care (SoC) vs. pembrolizumab alone
1.18 [0.99; 1.40] 1.18 [0.99;1.40]Standard of Care (SoC) vs. pembrolizumab alone
1.18 [0.99; 1.40] Standard of Care (SoC) vs. pembrolizumab plus SoC
1.18 [1.00; 1.39] 1.18 [1.00;1.39]Standard of Care (SoC) vs. pembrolizumab plus SoC
1.18 [1.00; 1.39] Standard of Care (SoC) placebo plus SoC pembrolizumab alone nivolumab plus SoC pembrolizumab plus SoC direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) placebo plus SoC pembrolizumab alone nivolumab plus SoC pembrolizumab plus SoC Standard of Care (SoC) --- NA 1.18 0.99; 1.401.31 1.16; 1.491.18 1.00; 1.39placebo plus SoC NA --- NA NA NA pembrolizumab alone 0.85 0.71; 1.01NA --- 1.12 0.90; 1.381.00 0.79; 1.27nivolumab plus SoC 0.76 0.67; 0.86NA 0.90 0.73; 1.11--- 0.89 0.73; 1.10pembrolizumab plus SoC 0.85 0.72; 1.00NA 1.00 0.79; 1.271.12 0.91; 1.37---
pathologies: 122,271,262,260,219,184
- treatments: 873
result logic